# Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects

> **NCT02191176** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dextromethorphan syrup - low dose
- **DRUG:** Dextromethorphan syrup - high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02191176
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-07
- **Final completion:** —
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02191176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02191176, "Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02191176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*